Ellie J. C. Goldstein, MD, discusses the global threat of resistant gram-negative rods and recently approved drugs ceftolozane tazobactam and ceftazidime avibactam.
Segment Description: Ellie J. C. Goldstein, MD, director of the R.M. Alden Research Laboratory and clinical professor at the UCLA School of Medicine, discusses the global threat of resistant gram-negative rods and recently approved drugs ceftolozane tazobactam and ceftazidime avibactam.
Interview Transcript (modified slightly for readability):
“The Infectious Disease Society of America (IDSA) noted that resistance was increasing and the US Centers for Disease Control and Prevention (CDC) has made resistant gram-negative rods an urgent global threat. The IDSA initiated at least 2 programs: 1 was 10 x ‘20—having 10 new drugs by 2020—and the other is the ‘Bad Bugs, No Drugs’; both of these highlight the problem that there is a lot of resistance developed in the gram-negative sphere in particular.
This may be less of a problem in the United States and more of a problem elsewhere but with international travel and people going on vacation and flying back, they bring their microbiome from where they have visited [back] home. And so, resistance has been increasing worldwide and in the United States.
As part of the effort to get those ‘10 by 20,’ 2 new gram-negative drugs have been recently approved by the US Food and Drug Administration (FDA); one [is] ceftolozane tazobactam and the other [is] ceftazidime avibactam and they are part of this effort to get new drugs for resistant gram-negative infections. These drugs are actually very different—they’re not interchangeable; they’re not the same.
Ceftolozane is a new cephalosporin. Some people might call it a fifth generation, with an old b-lactamase inhibitor tazobactam, and its particular strength is against resistant Pseudomonas, including ceftazidime-resistant Pseudomonas.
Ceftazidime avibactam is a drug with an old cephalosporin but a new b-lactamase inhibitor that has particular strength against carbapenem-resistant Enterobacteriaceae (CREs) like Klebsiella pneumonia.
The 2 drugs have different niches in the therapeutic armamentarium and so, each 1 is different and depends on what you want to treat; you want to be specific for your individual patient depending on their isolate and their disease.”
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.